- Home
- WFG vs TNGX Comparison
WFG vs TNGX Comparison
Compare WFG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | TNGX |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WFG | TNGX |
|---|---|---|
| Price | $68.32 | $22.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $89.50 | $21.78 |
| AVG Volume (30 Days) | 168.2K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $57.34 | $6.25 |
| 52 Week High | $76.99 | $34.39 |
Technical Indicators
Market Signals| Indicator | WFG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 36.92 |
| Support Level | $67.41 | $19.74 |
| Resistance Level | $72.20 | $26.38 |
| Average True Range (ATR) | 2.15 | 1.38 |
| MACD | -0.13 | -0.12 |
| Stochastic Oscillator | 46.04 | 21.06 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.